Analyst Reco. Arvinas, Inc.

Equities

ARVN

US04335A1051

Real-time Estimate Cboe BZX Other stock markets 09:22:49 03/05/2024 pm IST			5-day change	1st Jan Change
33.02 ^USD	+1.80%		+1.88%	-19.87%

24/04	Arvinas, Inc. Appoints Randy Teel as Chief Business Officer	CI
15/04	H.C. Wainwright Cuts Price Target on Arvinas to $87 From $90, Maintains Buy Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

H.C. Wainwright Cuts Price Target on Arvinas to $87 From $90, Maintains Buy Rating	15/04	MT
HC Wainwright Adjusts Arvinas' Price Target to $87 From $90, Keeps Buy Rating	12/04	MT
Wedbush Adjusts Arvinas' Price Target to $57 From $59, Keeps Outperform Rating	11/04	MT
Barclays Adjusts Arvinas' Price Target to $60 From $26, Maintains Overweight Rating	29/02	MT
BMO Capital Adjusts Arvinas' Price Target to $90 From $89, Maintains Outperform Rating	28/02	MT
Oppenheimer Adjusts Arvinas Price Target to $80 From $95, Maintains Outperform Rating	28/02	MT
Wedbush Raises Arvinas' PT to $59 From $33, Sees 'Strong' Set Up in 2024; Keeps Outperform Rating	28/02	MT
Citigroup Downgrades Arvinas to Neutral From Buy, Adjusts Price Target to $55 From $36	14/02	MT
Wells Fargo Upgrades Arvinas to Overweight From Equalweight, Price Target to $63	19/12	MT
Jefferies Upgrades Arvinas to Buy From Hold, Raises Price Target to $40 From $32	06/12	MT
Wedbush Raises Arvinas' PT to $33 From $24, Says Vepdegestrant Combined With Palbociclib for Potential Breast Cancer Treatment Continues to Impress; Maintains Outperform Rating	06/12	MT
Guggenheim Upgrades Arvinas to Buy From Neutral, Price Target is $40	20/11	MT
Morgan Stanley Adjusts Price Target on Arvinas to $20 From $32, Reiterates Equalweight Rating	13/11	MT
Citigroup Adjusts Arvinas' Price Target to $36 From $72, Maintains Buy Rating	24/23/24	MT
Barclays Adjusts Price Target on Arvinas to $26 From $39, Keeps Overweight Rating	24/23/24	MT
Wedbush Upgrades Arvinas to Outperform From Neutral After Recent Sell-Off, Notes Plans to De-Prioritize Bavdegalutamide in Favor of ARV-766; Adjusts PT to $24 From $27	23/23/23	MT
Citigroup Adjusts Arvinas Price Target to $72 From $77, Maintains Buy Rating	21/23/21	MT
Morgan Stanley Adjusts Price Target on Arvinas to $32 From $35, Maintains Equal-Weight Rating	14/23/14	MT
Barclays Lowers Price Target on Arvinas to $39 From $70, Maintains Overweight Rating	09/23/09	MT
UBS Adjusts Arvinas Price Target to $90 From $151, Maintains Buy Rating	17/23/17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Arvinas, Inc.

Equities

ARVN

US04335A1051

Analyst Reco.

Filters